The AAFP recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonscopy, in adults, beginning at age 50 years and continuing until age 75 years. The risk and benefits of these screening methods vary. (2008)
(Grade: A recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm
This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Colorectal Cancer
Colorectal Cancer, Adults
Colorectal Cancer, Adults
The AAFP recommends against routine screening for colorectal cancer in adults age 76 to 85 years. There may be considerations that support colorectal caner screening in an individual patient. (2008)
(Grade: C recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm
(Grade: C recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm
Colorectal Cancer, Adults
The AAFP recommends against screening for colorectal cancer in adults older than age 85 years. (2008)
(Grade: D recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm
(Grade: D recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm
Colorectal Cancer, Chemo Prevention
The AAFP recommends against the routine use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) to prevent colorectal cancer in individuals at average risk for colorectal cancer. (2008)
(Grade: C recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasco.htm
(Grade: C recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspsasco.htm
Colorectal Cancer, Chemo Prevention, DNA Testing
The AAFP concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic colongraphy and fecal DNA testing as screening modalities for colorectal cancer. (2008)
(Grade: I recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm
(Grade: I recommendation)
Grade Definition: http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
Clinical Considerations: http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm
Colorectal Cancer, Genomic Testing
The AAFP recommends offering genetic testing for Lynch syndrome to patients newly diagnosed with colorectal cancer to reduce morbidity and mortality in relatives. Genetic testing should be offer to first degree relatives of those found to have Lynch syndrome, and those positive for Lynch syndrome should be offered earlier and more frequent screening for colorectal cancer. (2012)
Clinical considerations: http://www.egappreviews.org/docs/EGAPPWG-LynchRec.pdf (7-page PDF. About PDFs)
Clinical considerations: http://www.egappreviews.org/docs/EGAPPWG-LynchRec.pdf (7-page PDF. About PDFs)
